Ryvu Therapeutics S.A.
RVU.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | PLN 14,918 | PLN 12,403 | PLN 16,933 | PLN 25,545 |
| % Growth | 20.3% | -26.8% | -33.7% | – |
| Cost of Goods Sold | PLN 43,476 | PLN 3,377 | PLN 3,708 | PLN 5,860 |
| Gross Profit | -PLN 28,558 | PLN 9,026 | PLN 13,225 | PLN 19,685 |
| % Margin | -191.4% | 72.8% | 78.1% | 77.1% |
| R&D Expenses | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| G&A Expenses | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| SG&A Expenses | PLN 0 | PLN 0 | PLN 673 | PLN 1,108 |
| Sales & Mktg Exp. | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Other Operating Expenses | PLN 1,118 | PLN 36,700 | PLN 50,243 | PLN 59,096 |
| Operating Expenses | PLN 1,118 | PLN 36,700 | PLN 50,916 | PLN 60,204 |
| Operating Income | -PLN 29,676 | -PLN 27,674 | -PLN 37,691 | -PLN 40,519 |
| % Margin | -198.9% | -223.1% | -222.6% | -158.6% |
| Other Income/Exp. Net | PLN 4,969 | -PLN 5,981 | PLN 12,429 | PLN 5,623 |
| Pre-Tax Income | -PLN 24,707 | -PLN 33,655 | -PLN 25,262 | -PLN 34,896 |
| Tax Expense | PLN 0 | PLN 3 | PLN 14 | PLN 156 |
| Net Income | -PLN 24,707 | -PLN 33,658 | -PLN 25,276 | -PLN 35,052 |
| % Margin | -165.6% | -271.4% | -149.3% | -137.2% |
| EPS | -1.1 | -1.5 | -1.09 | -1.52 |
| % Growth | 26.7% | -37.6% | 28.3% | – |
| EPS Diluted | -1.1 | -1.5 | -1.1 | -1.52 |
| Weighted Avg Shares Out | 22,461 | 22,439 | 23,120 | 23,120 |
| Weighted Avg Shares Out Dil | 22,461 | 22,439 | 23,120 | 23,120 |
| Supplemental Information | – | – | – | – |
| Interest Income | PLN 1,284 | PLN 1,278 | PLN 1,639 | PLN 1,984 |
| Interest Expense | PLN 2,059 | PLN 2,985 | PLN 1,655 | PLN 1,683 |
| Depreciation & Amortization | PLN 2,858 | PLN 2,295 | PLN 2,423 | PLN 2,523 |
| EBITDA | -PLN 19,790 | -PLN 28,375 | -PLN 21,184 | -PLN 30,689 |
| % Margin | -132.7% | -228.8% | -125.1% | -120.1% |